Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab"

J Dtsch Dermatol Ges. 2010 Jan;8(1):65-6. doi: 10.1111/j.1610-0387.2009.07312_supp.x.
[Article in English, German]

Abstract

In February 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) had recommended the suspension of efalizumab's (Raptiva) marketing authorization, because its benefits in the treatment of psoriasis were modest, while there was a risk of serious side effects in patients receiving the medicine, including the occurrence of progressive multifocal leukoencephalopathy (PML). The guideline group has changed the guideline accordingly.

Publication types

  • Practice Guideline

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Dermatology / standards*
  • European Union
  • Evidence-Based Medicine*
  • Humans
  • Practice Guidelines as Topic*
  • Psoriasis / drug therapy*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • efalizumab